Jacobs Levy Equity Management
ATNM icon

Jacobs Levy Equity Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Jacobs Levy Equity Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-953
Closed -$21K – 978
2018
Q3 		$21K Hold
953
– – ﹤0.01% 974
2018
Q2 		$18K Buy
+953
New +$12.1K ﹤0.01% 1010

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Jacobs Levy Equity Management's ATNM Position: Q4 2018 in Review

Jacobs Levy Equity Management sold out of Actinium Pharmaceuticals (ATNM) in Q4 2018, closing a stake of 953 shares — an estimated $21K sold.

Jacobs Levy Equity Management first reported a position in ATNM in Q2 2018 and held it in 2 quarters. The position peaked at $21K in Q3 2018. 43 funds tracked by Wall St. Rank hold ATNM as of Q4 2018.

  • Jacobs Levy Equity Management reported no remaining Actinium Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 953 Actinium Pharmaceuticals shares in Q4 2018, an estimated $21K.
  • Jacobs Levy Equity Management first reported a position in Actinium Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Actinium Pharmaceuticals position peaked at $21K in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2018, filed 14 Feb 2019.